Evidence map›Paper›PMID 32193325›Full record

ArticleScience (New York, N.Y.)2020

Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work.

A Westbrook, R van den Bosch, J I Määttä, L Hofmans, D Papadopetraki, R Cools, M J Frank

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Dopamine and Temporal Discounting: Revisiting Pharmacology and Individual Differences.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Methylphenidate undermines or enhances divergent creativity depending on baseline dopamine synthesis capacity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

A WestbrookDepartment of Cognitive, Linguistic, and Psychological Sciences, Brown University, Providence, RI, USA. andrew.westbrook@brown.edu.ORCID 0000-0002-7956-2609
R van den BoschRadboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Nijmegen, Netherlands.ORCID 0000-0002-3994-8291
J I MäättäRadboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Nijmegen, Netherlands.ORCID 0000-0002-1130-0557
L HofmansRadboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Nijmegen, Netherlands.ORCID 0000-0001-7259-6243
D PapadopetrakiRadboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Nijmegen, Netherlands.ORCID 0000-0001-8278-3886
R Cools *Radboud University, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Nijmegen, Netherlands.ORCID 0000-0001-8994-5534
M J Frank *Department of Cognitive, Linguistic, and Psychological Sciences, Brown University, Providence, RI, USA.ORCID 0000-0001-8451-0523

Funding

Clinical and Computational Studies of Dopamine Function in SchizophreniaR01MH080066 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOLD, JAMES M. · 2008 to 2017
$6.4M
Brain Science Compute ClusterS10OD025181 · OD · BROWN UNIVERSITY · PI SANES, JEROME N · 2019 to 2019
$600k
Dopamine and a Bias for Proximal Action in Cognitive EffortF32MH115600 · NIMH · BROWN UNIVERSITY · PI WESTBROOK, JOHN ANDREW · 2018 to 2020
$188k
EPA EP-C-14-005NIMH NIH HHS F32 MH115600NIMH NIH HHS R01 MH080066
6 · The paper itself

Abstract

Stimulants such as methylphenidate are increasingly used for cognitive enhancement but precise mechanisms are unknown. We found that methylphenidate boosts willingness to expend cognitive effort by altering the benefit-to-cost ratio of cognitive work. Willingness to expend effort was greater for participants with higher striatal dopamine synthesis capacity, whereas methylphenidate and sulpiride, a selective D2 receptor antagonist, increased cognitive motivation more for participants with lower synthesis capacity. A sequential sampling model informed by momentary gaze revealed that decisions to expend effort are related to amplification of benefit-versus-cost information attended early in the decision process, whereas the effect of benefits is strengthened with higher synthesis capacity and by methylphenidate. These findings demonstrate that methylphenidate boosts the perceived benefits versus costs of cognitive effort by modulating striatal dopamine signaling.

Indexed as

AdolescentCaudate NucleusChoice BehaviorCognitionCorpus StriatumDecision MakingDopamineDopamine D2 Receptor AntagonistsDopamine Uptake InhibitorsFemaleFixation, OcularHumansMaleMemoryMethylphenidateMotivationDopamineDopamine D2 Receptor AntagonistsDopamine Uptake InhibitorsMethylphenidateSulpiride

Identifiers

PMID32193325
PMCPMC7430502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.